Companies › Shanghai IASO Biotechnology
1 active drug program in 2 registered trials: 2 Phase 1; Hematology, Immunology; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| IASO-782 injection | – | Phase 1 | SLE - Systemic Lupus Erythematosus; Autoimmune Thrombocytopenia | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07483346 | IASO-782 injection | Phase 1 | SLE - Systemic Lupus Erythematosus | Immunology | Aug 2027 |
| NCT06534021 | IASO-782 injection | Phase 1 | Autoimmune Thrombocytopenia | Hematology | Oct 2027 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.